Industry Reports
Sun Pharma to acquire Biosintez in RussiaÂ
Sun Pharma announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. ...
Industry Reports
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
Novartis announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study,...
Industry Reports
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group’s Methotrexate Injection Products
Cumberland Pharmaceuticals , a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s innovative injectable methotrexate product line. The products are designed for the treatment of...
Industry Reports
Sorrento’s TNK Therapeutics Subsidiary to Acquire Virttu Biologics
Sorrento Therapeutics, Inc. Virttu, based in Glasgow, Scotland, is a privately-held biopharmaceutical company focused on the development of oncolytic virus therapy for treatment of cancer. Virttu's lead product candidate Seprehvir® (HSV1716) is a Herpes Simplex Virus...
Industry Reports
CSL Behring Presents Positive Results from CSL112 Phase 2b Trial
CSL Limited -At the American Heart Association (AHA) Scientific Sessions in New Orleans, Louisiana, held on 15 November 2016, CSL Behring announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a...
Industry Reports
Multi Packaging Solutions completes two strategic acquisitions: AJS Labels and i3 Plastic Cards
Multi Packaging Solutions a global leader in value-added print and packaging solutions for the healthcare, branded consumer, and multi-media markets, has completed two strategic acquisitions that complement other operations within MPS and further extend the range of products the...
Industry Reports
Lexicon Pharmaceuticals acquires exclusive rights to development candidate for Neuropathic pain from its alliance with Bristol-Myers Squibb
Lexicon Pharmaceuticals Inc announced that it has obtained exclusive research, development and commercialization rights to LX9211 (BMS-986176), a development candidate for neuropathic pain that was jointly developed by Lexicon and Bristol-Myers Squibb Company as part of their neuroscience drug...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read